Post The Parker Institute touts early results in pancreatic cancer trial — and a new model to accelerate drug development
Post The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research A Conversation With Jeffrey Bluestone, PhD
Post Friends and Parker Institute for Cancer Immunotherapy Co-Host Summit: Optimizing the Use of Immunotherapy